Trial Condition(s):

Atrial Fibrillation

Xarelto for prevention of stroke in patients with atrial fibrillation in Asia (XANAP)

Bayer Identifier:

16371

ClinicalTrials.gov Identifier:

NCT01750788

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

Inclusion Criteria
:
 -  Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study.
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
2297
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Indonesia

Status
Completed
 
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 
Locations

Investigative Site

Many Locations, India

Status
Terminated
 
Locations

Investigative Site

Many Locations, Taiwan, China

Status
Completed
 
Locations

Investigative Site

Many Locations, Hong Kong, China

Status
Completed
 
Locations

Investigative Site

Many Locations, Malaysia

Status
Completed
 
Locations

Investigative Site

Many Locations, Philippines

Status
Completed
 
Locations

Investigative Site

Many Locations, Singapore

Status
Completed
 
Locations

Investigative Site

Many Locations, Thailand

Status
Completed
 
Locations

Investigative Site

Many Locations, Vietnam

Status
Completed
 
Locations

Investigative Site

Many Locations, Pakistan

Status
Completed
 

Trial Design